Get notified of page updates

Treatment before surgery for people with early-stage breast cancer & a BRCA1, BRCA2 or PALB2 mutation

Clinicaltrials.gov identifier:
NCT04584255
PRINTER FRIENDLY PAGE

Treating Early-Stage HER2-Negative Breast Cancer with a PARP Inhibitor (Niraparib) and Immunotherapy (Dostarlimab) in People with a BRCA or PALB2 Mutation

Treatment before surgery for people with early-stage breast cancer & a BRCA1, BRCA2 or PALB2 mutation

Clinicaltrials.gov identifier:
NCT04584255
PRINTER FRIENDLY PAGE
Overview
Who Can Join
Glossary on
off

About the Study

NOTE: This study is no longer enrolling patients. 

This study will look at how well the drugs  (a type of known as a ) and Dostarlimab (a type of ) treat breast cancer in people with an inherited ,  or mutation. 

 

This Study is Open To:

NOTE: This study is no longer enrolling patients. 

This Study is NOT Open To:

NOTE: This study is no longer enrolling patients.